Related Experiment Video

Updated: Dec 13, 2025

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

234

Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis: Data From the Pediatric Primary Sclerosing

Trevor J Laborda1, Amanda Ricciuto2, Madeleine Aumar3

  • 1University of Utah and Intermountain Primary Children's Hospital, Salt Lake City, UT.

Journal of Pediatric Gastroenterology and Nutrition
|August 3, 2020
PubMed

Insights

Vedolizumab (VDZ) did not improve liver outcomes in pediatric patients with primary sclerosing cholangitis and inflammatory bowel disease (PSC-IBD). Liver disease worsened in those with medically refractory IBD, suggesting progressive liver damage.

Area of Science:

  • Gastroenterology
  • Hepatology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) frequently co-occurs with inflammatory bowel disease (IBD).
  • Vedolizumab (VDZ), an anti-α4β7 integrin antibody, targets lymphocyte homing to the gut and liver via MAdCAM-1.
  • Investigating VDZ's efficacy in pediatric PSC-IBD patients is crucial due to shared pathophysiology.

Purpose of the Study:

  • To evaluate liver outcomes in pediatric patients with PSC-IBD treated with VDZ.
  • To assess the impact of VDZ on liver biochemistry and IBD activity in this cohort.
  • To identify factors associated with liver response to VDZ therapy.

Main Methods:

  • Retrospective analysis of 37 pediatric patients with PSC-IBD from the Pediatric PSC Consortium.
  • Collection of demographic, clinical, biochemical, radiological, and histopathological data up to 1 year of VDZ therapy.
  • Definition of liver biochemical response as a ≥75% reduction in GGT or GGT <50 IU/L; IBD response as improved endoscopic/activity scores.

Main Results:

  • 22% of patients with abnormal baseline GGT achieved liver biochemical response.
  • 32% achieved IBD remission, 30% clinical response, and 38% no response.
  • Liver biochemistry worsened in VDZ-unresponsive IBD patients but remained stable in those in remission (P=0.066).

Conclusions:

  • Vedolizumab did not demonstrate significant improvement in liver biochemistry for pediatric PSC-IBD patients.
  • Progressive liver disease may be more prevalent in patients with medically refractory IBD.
  • VDZ's efficacy in improving liver outcomes in pediatric PSC-IBD warrants further investigation.
Abstract

More Related Videos

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.3K
Isolation of Neonatal Extrahepatic Cholangiocytes07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

10.7K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
364
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
341
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
206
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
343
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
328
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
351